Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
LifeTech Scientific Corporation ( (HK:1302) ) has shared an update.
LifeTech Scientific Corporation has announced that its Congenital Heart Defect Occluder has been admitted into the National Medical Products Administration’s Special Examination and Approval Procedure for Innovative Medical Devices. This marks the company’s 16th product to achieve such recognition, highlighting its commitment to advancing medical technology for congenital heart diseases. The occluder, designed with a full nitinol metal structure, offers a bidirectional release mechanism, enhancing treatment options for patients with patent ductus arteriosus (PDA). This development is expected to expedite the product’s registration and launch, benefiting PDA patients and expanding LifeTech’s product portfolio.
The most recent analyst rating on (HK:1302) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation operates in the medical device industry, focusing on innovative solutions for congenital heart defects. The company is known for its development of minimally invasive medical devices, particularly those addressing congenital heart conditions.
Average Trading Volume: 43,031,395
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.85B
For an in-depth examination of 1302 stock, go to TipRanks’ Overview page.